Share

September 2021; 8 (5) ArticleOpen Access

Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis

A Randomized, Controlled Trial

Helene Højsgaard Chow, Jacob Talbot, Henrik Lundell, Camilla Gøbel Madsen, Lisbet Marstrand, Theis Lange, Mie Reith Mahler, Sophie Buhelt, Rikke Holm Hansen, Morten Blinkenberg, Jeppe Romme Christensen, Per Soelberg Sørensen, Marina Rode von Essen, Hartwig Roman Siebner, Finn Sellebjerg
First published August 24, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001037
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1326

Share

Article Figures & Data

Figures

  • Figure 1
    Figure 1 Trial Profile
  • Figure 2
    Figure 2 Comparison of Biomarkers Between Patients With PPMS and Symptomatic Controls

    This figure shows concentrations of NFL, MBP, CHI3L1, sCD14, sCD27, and BCMA in CSF at screening in patients with PPMS (n = 59) and symptomatic controls (NFL, CHI3L1, and BCMA n = 35; MBP n = 31).18 The symptomatic controls were all included in the validation study of the immunoassays used for measuring CHI3L1, sCD14, sCD27, and BCMA.38 The patients with PPMS were older (p < 0.001) and more commonly male than the symptomatic controls (p = 0.001). p-values are based on ANCOVA with correction for age and sex. ANCOVA = analysis of covariance; sBCMA = soluble B-cell maturation antigen; MBP = myelin basic protein; NFL = neurofilament light chain; PPMS = primary progressive MS; sCD14 = soluble CD14; sCD27 = soluble CD27.

Tables

  • Table 1
  • Table 2
  • Table 3
  • Table

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles